Both the companies will be responsible for jointly developing products which will be commercialized by Amerigen in the US. As part of the deal, Menovo will oversee manufacturing
Limitx is a new, early stage technology apart from the company’s other abuse deterrent technologies Aversion and Impede. The NIDA grant is based on a proposal submitted by
Velphoro, a non-calcium, iron-based, chewable phosphate binder, was issued a positive opinion in June 2014 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use
Daklinza is approved for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 to treat HCV infection in adults. The combination of Daklinza
The randomized, double-blind, placebo-controlled trial is divided into two treatment arms, MN-166 and matching placebo, and includes a six-month treatment period followed by a six-month open-label extension. The
The grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI), which is a division of the National Institutes of Health (NIH). Patients suffering from IPF
The Phase IIa trial will include a total of seven experienced Alzheimer’s disease clinical trial sites in Melbourne. The company has submitted the clinical trial including the initiation
Jardiance, a once-daily, 10mg or 25mg tablet, was approved by the US Food and Drug Administration (FDA) on 1 August 2014 as an adjunct to diet and exercise
The three-chamber PN bags help in delivering these nutrients in volumes and concentrations that meet the nutritional needs of most patients. For patients who cannot digest or absorb
The new drug product, AVP-786, is a combination of deuterium modified dextromethorphan and ultra-low dose quinidine. The payment is result of the initiation of dosing by Avanir in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.